See the DrugPatentWatch profile for ozempic

Yes, it is recommended to monitor for pancreatitis symptoms while taking Ozempic (generic name: semaglutide) [1]. Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is used to improve glycemic control in adults with type 2 diabetes [2].

According to the prescribing information for Ozempic, pancreatitis has been reported in clinical trials [3]. Therefore, it is important to monitor for pancreatitis symptoms while taking this medication. Symptoms of pancreatitis may include persistent severe abdominal pain, sometimes radiating to the back, which may be accompanied by nausea, vomiting, and/or fever [3].

If pancreatitis is suspected, Ozempic should be discontinued and appropriate management should be initiated [3]. It is important to note that Ozempic has a boxed warning for thyroid C-cell tumors [3].

In summary, while taking Ozempic, it is important to monitor for pancreatitis symptoms and seek medical attention if they occur. Additionally, patients should be aware of the risk of thyroid C-cell tumors associated with this medication.

Sources:
[1] DrugPatentWatch.com. (n.d.). Ozempic (semaglutide) - DrugPatentWatch. Retrieved from <https://www.drugpatentwatch.com/drugs/ozempic>
[2] Novo Nordisk. (2021). Ozempic (semaglutide) injection 0.5 mg or 1 mg. Retrieved from <https://www.novo-pi.com/ozempic.pdf>
[3] U.S. Food and Drug Administration. (2017). Highlights of prescribing information: Ozempic (semaglutide) injection. Retrieved from <https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209171s000lbl.pdf>